Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
KZR Stock Chart & Stats
$6.50
-$0.28(-4.09%)
At close: 4:00 PM EST
$6.50
-$0.28(-4.09%)
Day’s Range― - ―
52-Week Range$3.53 - $6.91
Previous CloseN/A
Volume19.48K
Average Volume (3M)297.79K
Market Cap
$46.14M
Enterprise Value-$55.29M
Total Cash (Recent Filing)$90.22M
Total Debt (Recent Filing)$9.91M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 12, 2026EPS Estimate
-1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding7,323,156
10 Day Avg. Volume813,550
30 Day Avg. Volume297,789
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)4.19
Price to Sales (P/S)0.00
P/FCF Ratio-6.60
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit115.67
Enterprise Value/Ebitda0.93
Forecast
1Y Price Target
$6.00Price Target Upside-7.69% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash PositionA cash balance of about $90.2 million could attract potential acquirers and support a takeover valuation that establishes a near-term floor for the share price.
Clinical DataPositive safety and efficacy results from the PORTOLA phase II randomized trial in relapsed or refractory autoimmune hepatitis reinforce the therapeutic value of the lead program beyond cash holdings.
Shareholder ProtectionsExtension of the shareholder rights plan preserves the integrity of the strategic review process and gives the board flexibility to evaluate acquisition proposals that could unlock shareholder value.
Bears Say
Analyst RepricingAnalyst reductions in probability of success to about 10% for the autoimmune hepatitis program and a cut in the price target to roughly cash-per-share reflect materially lower expectations for future upside from the clinical program.
Development DelaysThe FDA's request for a stand-alone pharmacokinetic study in patients with significant liver impairment is expected to delay resumption of autoimmune hepatitis trials by roughly two years, postponing potential approval milestones.
Regulatory SetbackFailure to align with the FDA on a registrational pathway and cancellation of a scheduled Type C meeting creates significant regulatory uncertainty for the lead drug.
Kezar Life Sciences News
KZR FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was $3.53 and its highest was $6.91 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Kezar Life Sciences Inc’s market cap is $46.14M.
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Mar 12, 2026 which is in 62 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on Nov 12, 2025. The company reported -$1.53 earnings per share for the quarter, beating the consensus estimate of -$2.058 by $0.528.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Overvalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -1.49.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 7,323,156 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -$1.53 in its last earnings report, beating expectations of -$2.058. Following the earnings report the stock price went down -0.162%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Currently, no hedge funds are holding shares in KZR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kezar Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (-7.69% Downside)
$6.00 (-7.69% Downside)
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.05%
12-Months-Change
Fundamentals
Return on Equity
-56.86%
Trailing 12-Months
Asset Growth
-39.35%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
KZR Stock 12 Month Forecast
Average Price Target
$6.00
▼(-7.69% Downside)
Technical Analysis
Ownership Overview
25.19% Insiders
10.90% Mutual Funds
45.21% Other Institutional Investors
14.32% Public Companies and
Individual Investors